Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia

NCT02530476 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

17

Enrollment

OTHER

Sponsor class

Conditions

Leukemia
Acute Myeloid Leukemia

Interventions

DRUG: Selinexor
DRUG: Sorafenib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]